|
|
Volumn 485, Issue 7399, 2012, Pages 426-427
|
|
US government sets out Alzheimer's plan
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMYLOID BETA PROTEIN;
CRENEZUMAB;
DNA;
ALZHEIMER DISEASE;
DISEASE COURSE;
EXOME;
FOLLOW UP;
GENETIC PREDISPOSITION;
HEALTH CARE COST;
HUMAN;
MICROGLIA;
MUTATION;
NOTE;
PHASE 2 CLINICAL TRIAL (TOPIC);
PLURIPOTENT STEM CELL;
PRIORITY JOURNAL;
PROGNOSIS;
UNITED STATES;
ALZHEIMER DISEASE;
ANTIBODIES, MONOCLONAL;
BIOMEDICAL RESEARCH;
BUDGETS;
CLINICAL TRIALS AS TOPIC;
COLOMBIA;
FEDERAL GOVERNMENT;
GENETIC PREDISPOSITION TO DISEASE;
HUMANS;
NATIONAL INSTITUTES OF HEALTH (U.S.);
TIME FACTORS;
UNITED STATES;
|
|
EID: 84861418086
PISSN: 00280836
EISSN: 14764687
Source Type: Journal
DOI: 10.1038/485426a Document Type: Note |
|
Times cited : (29)
|
|
References (0)
|
